专利检索 ap:("CSL Behring LLC") AND inv:"Voigt, Christine" 第 1 页

1.

发明公开
A1AT FOR REDUCING RISK OF ONSET OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATION 审中-实审

公开(公告)号：EP4321220A3

公开(公告)日：2024-03-20

申请号：EP23209713.9

申请日：2018-11-30

申请人： CSL Behring LLC

发明人： Uknis, Marc , Voigt, Christine , Baheti, Gautam , Roberts, John

IPC分类号： A61K38/57 , A61P37/06 , A61K45/06 , C07K16/00

摘要： This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A 1A or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.

2.

发明公开
A1AT FOR REDUCING RISK OF ONSET OF ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATION 审中-公开

公开(公告)号：EP4321220A2

公开(公告)日：2024-02-14

申请号：EP23209713.9

申请日：2018-11-30

申请人： CSL Behring LLC

发明人： Uknis, Marc , Voigt, Christine , Baheti, Gautam , Roberts, John

IPC分类号： A61P37/06

摘要： This disclosure relates to methods for preventing or reducing the risk of development of graft versus host disease (GVHD) in patients receiving hematopoietic cell transplantation (HCT) by particular methods of administering alpha-1 antitrypsin (A 1A or AAT) to patients both prior to and following and HCT procedure. The disclosure also relates to specific methods of treating acute GVHD (aGVHD) after HCT with A1AT.